Intech Investment Management LLC Makes New Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Intech Investment Management LLC purchased a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 28,228 shares of the company's stock, valued at approximately $3,226,000.

Several other institutional investors also recently added to or reduced their stakes in PCVX. Russell Investments Group Ltd. purchased a new stake in shares of Vaxcyte in the first quarter worth about $1,288,000. O Shaughnessy Asset Management LLC purchased a new stake in shares of Vaxcyte in the first quarter worth about $321,000. American International Group Inc. lifted its holdings in shares of Vaxcyte by 12.2% in the first quarter. American International Group Inc. now owns 52,313 shares of the company's stock worth $3,574,000 after buying an additional 5,686 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its stake in Vaxcyte by 163.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 18,064 shares of the company's stock valued at $1,234,000 after purchasing an additional 11,208 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Vaxcyte by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company's stock valued at $216,966,000 after purchasing an additional 498,359 shares in the last quarter. Institutional investors own 96.78% of the company's stock.

Vaxcyte Price Performance

NASDAQ:PCVX traded up $0.15 during trading hours on Friday, hitting $88.54. The company had a trading volume of 1,614,295 shares, compared to its average volume of 1,610,634. The company has a market capitalization of $11.04 billion, a PE ratio of -19.25 and a beta of 1.01. The stock has a 50-day moving average price of $107.89 and a 200 day moving average price of $89.57. Vaxcyte, Inc. has a 52 week low of $48.24 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same quarter in the prior year, the firm posted ($0.91) earnings per share. Analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PCVX has been the topic of a number of recent analyst reports. BTIG Research raised their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Needham & Company LLC reaffirmed a "buy" rating and issued a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, November 6th. Cantor Fitzgerald reissued an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Jefferies Financial Group lifted their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Finally, Mizuho lifted their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has an average rating of "Buy" and an average target price of $147.50.

Insider Activity at Vaxcyte

In other news, CEO Grant Pickering sold 7,098 shares of Vaxcyte stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $109.21, for a total value of $775,172.58. Following the completion of the transaction, the chief executive officer now owns 138,581 shares of the company's stock, valued at $15,134,431.01. The trade was a 4.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mikhail Eydelman sold 5,000 shares of Vaxcyte stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $109.27, for a total value of $546,350.00. Following the completion of the transaction, the senior vice president now directly owns 28,623 shares of the company's stock, valued at approximately $3,127,635.21. This represents a 14.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 102,464 shares of company stock worth $11,455,576 over the last quarter. Corporate insiders own 3.10% of the company's stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.